U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07884136) titled 'RBD1119 in Coronary Artery Disease (CAD)' on Oct. 13.
Brief Summary: CAD is driven by atherosclerosis in the coronary arteries and is a major cause of myocardial infarction, heart failure, arrhythmias, and premature death. Despite contemporary secondary prevention including lipid lowering, revascularization when indicated, and antiplatelet therapy, participants with established CAD, particularly those post-ACS, remain at clinically meaningful residual risk of recurrent atherothrombotic events.
Intensifying antithrombotic therapy can reduce ischemic events but typically increases bleeding, as exemplified by the addition of low dose ...